New York State Common Retirement Fund lessened its position in Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating) by 66.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 323,397 shares of the company's stock after selling 632,861 shares during the quarter. New York State Common Retirement Fund's holdings in Orchard Therapeutics were worth $230,000 at the end of the most recent reporting period.

Separately, SG Americas Securities LLC purchased a new stake in Orchard Therapeutics during the 4th quarter worth about $858,000. Institutional investors and hedge funds own 56.47% of the company's stock.

Analysts Set New Price Targets

Separately, Barclays cut their price target on Orchard Therapeutics from $6.00 to $4.00 in a report on Friday, May 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Orchard Therapeutics has an average rating of "Hold" and a consensus target price of $7.75.

Orchard Therapeutics Price Performance

Orchard Therapeutics Company Profile

(Get Rating)

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration.

Further Reading

• Get a free copy of the StockNews.com research report on Orchard Therapeutics (ORTX)
• 2 EV Suppliers Powering To Gains After Raising Views
• Applied Materials Results Show A Slowing Semiconductor Market
• MarketBeat: Week in Review 8/15 – 8/19
• Near-Term Headwinds Present An Opportunity In Ross Stores
• Apple's Stock Could Be On The Verge Of Another 30% Rally

Want to see what other hedge funds are holding ORTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orchard Therapeutics plc (NASDAQ:ORTX – Get Rating).

Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.